TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Tools for Teen Moms: Reducing Infant Obesity Risk
Brief Summary: The purpose of this social media group randomized trial (GRT) is to test the feasibility of our Baby Dayr for Teen Moms intervention to increase maternal responsiveness to infant cues and implement healthy feeding practices through development of a healthy feeding style.

Aim 1: Evaluate the feasibility and acceptability of the Baby Dayr intervention administered to the target population as it relates to their acceptance and satisfaction with the content, format, delivery, and use of social media.

Aim 2: Explore efficacy of the Baby Dayr intervention administered to adolescent mothers of infants 4 months of age or less as assessed by maternal responsiveness, feeding style, and feeding practices evaluated at the completion of the intervention using self-report methods.


Options:
A: Change in Infant Growth (Baby is less than 2 months; baby is 3 months; baby is 6 months)
B: Linear growth: Mean change from baseline in length-for-age Z-scores at at 9-, 12- and 15-months-old (Length-for-age Z-scores: Baseline (6 months-old), Month 9, Month 12 and Month 15)
C: N/A
D: Growth (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months); Hemoglobin (Measurements will be made for children between the ages of 3 and 12 months of age at baseline and then 2 years later, at endline, when the children are between the ages of 23 and 40 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Burkina Faso: a Cluster Randomized Intervention Study
Brief Summary: Globally, child undernutrition is the underlying cause for 3.1 million deaths of children younger than 5 years. 18.7 million children under five years of age suffer from severe acute malnutrition (SAM) and an additional 33 million children suffer from moderate acute malnutrition, and are at risk of developing SAM

In Sub-Saharan Africa, there is often poor integration between programs to treat child acute malnutrition and programs that focus on the prevention of acute and chronic undernutrition - resulting in many missed opportunities for using prevention platforms to screen and refer SAM children, or for using screening and referral platforms to provide prevention services.

This project will address two critical gaps related to the integration of preventive and treatment programs: 1) screening and treatment of MAM/SAM have not yet been systematically integrated into routine health-center visits or mainstreamed into community outreach programs; and 2) screening programs often do not offer any preventive services for those children found not to be suffering from MAM/SAM at the time of screening; mothers of children identified as non-MAM/SAM case are usually sent home without receiving any health or nutrition inputs and as a result, may fail to come back for screening because they do not see any tangible benefit associated with their participation in the screening. This project will specifically address these gaps by assessing the effect of an integrated approach consisting of higher screening coverage and preventive Behavior Change Communication (BCC) + Small-Quantity Lipid-based Nutrient supplementation (SQ-LNS) on both prevention and treatment of child undernutrition.


Options:
A: Prevalence of acute child malnutrition defined by WHZ<-2 or MUAC <125mm or bilateral pitting edema in children 0-17 months of age (After 24 months of program implementation); Screening coverage of acute child malnutrition (proportion of children monthly screened / total number of eligible children (aged 0-17 months) (monthly from study inclusion at 0 months to 17 months of age and at study endline); Incidence of child acute malnutrition defined by WHZ<-2 or MUAC<125mm (monthly from study inclusion at 0 months to 17 months of age); Compliance to treatment of acute malnutrition (% of cases that complete treatment over total admitted) (monthly from study inclusion at 0 months to 17 months of age and at study endline)
B: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
C: Length-for-Age Z-scores (Measured 24 months after intervention); Diarrhea Prevalence (Measured 12 and 24 months after intervention)
D: Child's consumption (Within 15 minutes)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Does the Use of a Videolaryngoscope Modifies Anesthetic Induction ?
Brief Summary: Videolaryngoscopes become widely used. The aim of this study is to compare anesthetic induction when patients are tracheally intubated using a MacGraph Mac videolaryngoscope or a conventional MacIntosh laryngoscope.

Tracheal intubation induces a nociceptive stimulation. Hypothesis is that the use of a videolaryngoscope induces a less pronounced nociceptive stimulation and, consequently, that it modifies the anesthetic drugs requirement. .


Options:
A: Required dose of opioid to counteract nociceptive stimulation (1 hour)
B: Peak forces during intubation (Intraoperatively)
C: Maximum cervical spine motion (degree) (During tracheal intubation time, an expected average of 90 seconds)
D: CERVICAL MOTIONS (January 2011 and December 2012)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone Application on Anxiety of Children
Brief Summary: Background: Preoperative Anxiety is a negative factor in anesthetic and surgical experience. Among the strategies for reducing children's anxiety, non-pharmacological strategies are as important as the pharmacological ones, but their its validity is still controversial.

Objectives: The aim of this study is to verify if the information provided to relatives as well as and smartphone application provided to children interferes in prevalence and level of child preoperative anxiety.

Methods: Eighty four children, 4-8 years old, ASA I, II and III, undergoing elective surgical procedures and their relatives are randomly allocated into four groups: control group (CG) where the relative received conventional information about anesthesia; info group (IG), relative received an information leaflet about anesthesia; device group (DG), relative received only conventional verbal information and the child received smartphone application immediately before entering the operating room; device and info group (DIG) relative received a leaflet containing information and the child received smartphone application. Children's anxiety will be assessed using the modified Yale Preoperative Anxiety Scale (m-YPAS) on three occasions: at the ward (W), surgical theater in the waiting room (WR) and at the operating room (OR). Statistics analysis will employ by Kruskall-Wallis and Mann-Whitney tests for prevalence and level of anxiety in the groups.


Options:
A: Patient's level of anxiety (at day 1)
B: Faces Pain Scale-Revised (FPS-R) (5 minute)
C: Child pain intensity (2 minutes after completion of the immunization series.)
D: Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone Application on Anxiety of Children Measure by m-YPAS. (24 hours before surgery)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly. A Randomized Controlled Trial.
Brief Summary: Total Hip Arthroplasty is equal to or better than Hemiarthroplasty in the treatment of displaced femoral neck fractures in the elderly-elderly


Options:
A: Number of Participants With Revision Surgery (Measured 2 years after original surgery)
B: Harris hip score (2 years)
C: hip function score (1 year)
D: Hip related complication rate (2 years); Health-related Quality of Life (2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly. A Randomized Controlled Trial.
Brief Summary: Total Hip Arthroplasty is equal to or better than Hemiarthroplasty in the treatment of displaced femoral neck fractures in the elderly-elderly


Options:
A: hip function score (1 year)
B: Composite variable comprising reoperation rate and mortality (1 to 2-year post-surgery)
C: Hip related complication rate (2 years); Health-related Quality of Life (2 years)
D: Harris hip score (2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact
Brief Summary: The eCMP Pilot aims to study the feasibility and potential effectiveness of an electronically-mediated CardioMetabolic Program (eCMP) for therapeutic lifestyle change among adults with or at high risk for type 2 diabetes, heart disease, and/or stroke.


Options:
A: Change in Weight from Baseline to 6 Months (Baseline and 6 Months); Change in Weight from Baseline to 30 Months (Baseline and 30 Months)
B: Weight Loss (Change from baseline to 18-months.)
C: Weight reduction (1 year)
D: Change in measure of Health-related quality of life from baseline to 6-months follow up. (6-months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: TRuSST: Treatment of Social Cognition in Schizophrenia Trial
Brief Summary: This study is a multi-site, prospective, parallel arm, double-blind, randomized, controlled clinical trial to assess the efficacy of an experimental software program targeting social cognitive abilities versus a computer-based software control. Both the study and the software being investigated meet the criteria of Non-Significant Risk.


Options:
A: Feasibility of a multisite trial using cognitive remediation (Measured at post-treatment)
B: Change in Spatial Cognition (Multiple scores are aggregated to arrive at a single composite score) (At 6 weeks and At 12 weeks); Change in Performance on the UCSD Performance-based Skills Assessment (Co-Primary Composite Measure) (At 6 weeks and At 12 weeks)
C: Work Activity (6 month and 12 month)
D: Cognitive performance as measured by a neuropsychological battery (Measured at Weeks 8, 14, and 8 and Month 6 follow-up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Does Meal Timing Affect Energy Expenditure
Brief Summary: The purpose of this study is to find out if meal timing affects calories burned and blood sugar levels.


Options:
A: Blood biomarkers (After two weeks, 3 and 6 months); Blood biomarkers (After two weeks, 3 and 6 months); Blood biomarker (After two weeks, 3 and 6 months); Blood biomarker (After two weeks, 3 and 6 months)
B: Changes in body weight (Kilograms) (Baseline and 16 weeks); Change in insulin resistance (Baseline and 16 weeks)
C: Fat loss and lean mass retention (14 weeks); Weight loss (14 weeks); Absolute changes in body composition (14 weeks)
D: Energy expenditure (calories burned) (2 days)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.
Brief Summary: The objective of this study is to evaluate if in the prevention of postoperative recurrence of ileal Crohn's disease immediate initiation of azathioprine postoperatively is superior to delayed (6- 12 mths.) introduction of azathioprine upon disease recurrence assessed by endoscopic criteria. The primary endpoint, disease recurrence, encompasses symptomatic and surgical recurrence as well as severe endoscopic lesions at the final, 2 year, assessment.


Options:
A: Endoscopic remission (Week 102)
B: Number of Subjects Without Mucosal Ulceration at Week 12 (Week 12)
C: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year (one year)
D: remission without corticosteroids and without surgical resection (month 6 and 12 after inclusion)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.
Brief Summary: The objective of this study is to evaluate if in the prevention of postoperative recurrence of ileal Crohn's disease immediate initiation of azathioprine postoperatively is superior to delayed (6- 12 mths.) introduction of azathioprine upon disease recurrence assessed by endoscopic criteria. The primary endpoint, disease recurrence, encompasses symptomatic and surgical recurrence as well as severe endoscopic lesions at the final, 2 year, assessment.


Options:
A: Percentage of Participants With Clinical Recurrence (CR) of Crohn's Disease (CD) Prior to or at Week 76 (Baseline up to Week 76)
B: Endoscopic recurrence of disease (18 months)
C: Prevention of severe endoscopic recurrence of Crohn's disease.
D: Endoscopic remission (Week 102)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.
Brief Summary: The objective of this study is to evaluate if in the prevention of postoperative recurrence of ileal Crohn's disease immediate initiation of azathioprine postoperatively is superior to delayed (6- 12 mths.) introduction of azathioprine upon disease recurrence assessed by endoscopic criteria. The primary endpoint, disease recurrence, encompasses symptomatic and surgical recurrence as well as severe endoscopic lesions at the final, 2 year, assessment.


Options:
A: Number of endoscopic recurrences (52 weeks after the begin of the study)
B: The primary endpoint was therapeutic failure at one year, defined as CDAI score ≥200 and an increase of ≥60 points from baseline, or study drug discontinuation due to lack of efficacy or intolerable adverse drug reaction. (12 months)
C: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year (one year)
D: Endoscopic remission (Week 102)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Brief Summary: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).


Options:
A: RT-PCR for influenza A virus in nasal secretion (2 days)
B: Growth of Geographic Atrophy (6 months); Decrease in Drusen Volume (6 Months)
C: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 (Baseline, Week 48); Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 (Baseline, Week 48)
D: Change From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 (Baseline, Week 48); Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 (Baseline, Week 48)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Brief Summary: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).


Options:
A: Change From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 (Baseline, Week 48); Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 (Baseline, Week 48)
B: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 (Baseline, Week 48); Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 (Baseline, Week 48)
C: Growth of Geographic Atrophy (6 months); Decrease in Drusen Volume (6 Months)
D: Change of geographic atrophy size to baseline (24 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis - a Randomized, Double-blind, Placebo-controlled, Prospective Study
Brief Summary: To evaluate the efficacy and safety of intravesical instillation of Lipotoxin for the treatment of IC/BPS


Options:
A: Change of the O'Leary-Sant symptom score (Baseline and 1 month)
B: Pain reduction or resolution within 10 treatment sessions, evaluated with the 0-10 Numeric Pain Rating Scale (0-10NPRS) (10 weeks or earlier on resolution)
C: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score (Baseline to 6 weeks and 6 to 12 weeks); Change in O'Leary-Sant Interstitial Cystitis Problem Index Score (Baseline to 6 weeks and 6 to 12 weeks)
D: Change From Baseline in Average Daily Pain Score at Week 6 (Baseline, Week 6)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Computer-aided Interlimb Force Coupling Training on Paretic Hand and Arm Motor Control Following Chronic Stroke
Brief Summary: The investigators hypothesized that bilateral handgrip force training would result in significant improvements in paretic hand, arm movements and daily functional performances. In order to investigate whether the improvement of paretic hand could facilitate the motor recovery of paretic arm and functional performances, the investigators also hypothesized that motor recovery and functional performances improvements of paretic arm and hand have strongly correlation.


Options:
A: Upper Extremity motor control of Fugl-Meyer Assessment (FMA-UE) (before and after 4 weeks intervention)
B: Physical activity of the lower and upper extremities (6 months)
C: Fugl-meyer assessment_upper extremity (Change from baseline in Fugl-Meyer assessment at 4 weeks after intervention)
D: Rating Scale Score (1 day)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Computer-aided Interlimb Force Coupling Training on Paretic Hand and Arm Motor Control Following Chronic Stroke
Brief Summary: The investigators hypothesized that bilateral handgrip force training would result in significant improvements in paretic hand, arm movements and daily functional performances. In order to investigate whether the improvement of paretic hand could facilitate the motor recovery of paretic arm and functional performances, the investigators also hypothesized that motor recovery and functional performances improvements of paretic arm and hand have strongly correlation.


Options:
A: Upper Extremity motor control of Fugl-Meyer Assessment (FMA-UE) (before and after 4 weeks intervention)
B: Motor Assessment Scale (18 months after inclusion)
C: modified Rankin Score (3 months)
D: Maximum torque around the knee joint; gait velocity

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)
Brief Summary: Primary Objective:

To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE

Secondary Objective:

To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE


Options:
A: Number of HAE Attacks (28 days)
B: Time-Normalized Number of Attacks (NNA) for Participants During a Treatment Period (Weeks 1 to 14 for treatment period 1 and 2)
C: Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) (24 weeks); Part 2: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE (Part 1: 24 weeks (Week 0 to 24 to 52), Part 2: 28 weeks (Week 24 to 52)); Part 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat Administered QD Over a 52- to up to 104-week Administration Period in Subjects With HAE. (Part 3: Week 52 to up to Week 104.)
D: The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1 (13 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Prosthesis Choice in Older Patients With a Dislocated Femoral Neck Fracture of the Hip
Brief Summary: The purpose of this study is to evaluate whether an uncemented hip prosthesis is as safe as an cemented hip prosthesis for patients undergoing total hip arthroplasty surgery following a displaced femoral neck fracture.


Options:
A: hip function score (1 year)
B: Harris hip score (2 years)
C: Hip related complication rate (2 years); Health-related Quality of Life (2 years)
D: Number of Participants With Revision Surgery (Measured 2 years after original surgery)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Prosthesis Choice in Older Patients With a Dislocated Femoral Neck Fracture of the Hip
Brief Summary: The purpose of this study is to evaluate whether an uncemented hip prosthesis is as safe as an cemented hip prosthesis for patients undergoing total hip arthroplasty surgery following a displaced femoral neck fracture.


Options:
A: Revision Surgery (Measured 2 years after original surgery)
B: Dislocation (1 year after index surgery)
C: visual analog scale (36 months); Harris hip score (36 months); Eq-5d index scores (36 months)
D: Hip related complication rate (2 years); Health-related Quality of Life (2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Osteoarthritis and Knee Pain in Japan
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug known as duloxetine in participants with chronic osteoarthritis (OA) and knee pain in Japan.


Options:
A: Pain reduction (16 weeks)
B: Composite responder analysis based on pain and patient global status, with or without physical function.
C: Change From Baseline on the Brief Pain Inventory (BPI) 24-Hour Average Pain Score (Baseline, Week 14)
D: Patient's Global Impressions of Improvement (PGI-I) at Week 12 (12 weeks)

Answer: C